Paula Ocaranza1, Marjorie C Golekoh2, Shayne F Andrew3, Michael H Guo4, Paul Kaplowitz5, Howard Saal6, Ron G Rosenfeld7, Andrew Dauber3, Fernando Cassorla1, Philippe F Backeljauw3, Vivian Hwa3. 1. Institute of Maternal and Child Research, School of Medicine, University of Chile, Santiago, Chile. 2. Pediatric Endocrinology, Children's Hospital of Michigan, Detroit, Michigan, USA. 3. Cincinnati Center for Growth Disorders, Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 4. Division of Endocrinology, Boston Children's Hospital and Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. 5. Division of Pediatric Endocrinology and Diabetes, Children's National Health System, Washington, District of Columbia, USA. 6. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 7. Department of Pediatrics, Oregon Health & Science University, Portland, Oregon, USA.
Abstract
BACKGROUND: The growth-promoting effects of IGF-I is mediated through the IGF-I receptor (IGF1R), a widely expressed cell-surface tyrosine kinase receptor. IGF1R copy number variants (CNV) can cause pre- and postnatal growth restriction or overgrowth. METHODS: Whole exome sequence (WES), chromosomal microarray, and targeted IGF1R gene analyses were performed on 3 unrelated children who share features of small for gestational age, short stature, and elevated serum IGF-I, but otherwise had clinical heterogeneity. Fluorescence-activated cell sorting (FACS) analysis of cell-surface IGF1R was performed on live primary cells derived from the patients. RESULTS: Two novel IGF1R CNV and a heterozygous IGF1R nonsense variant were identified in the 3 patients. One CNV (4.492 Mb) was successfully called from WES, utilizing eXome-Hidden Markov Model (XHMM) analysis. FACS analysis of cell-surface IGF1R on live primary cells derived from the patients demonstrated a ∼50% reduction in IGF1R availability associated with the haploinsufficiency state. CONCLUSION: In addition to conventional methods, IGF1R CNV can be identified from WES data. FACS analysis of live primary cells is a promising method for efficiently evaluating and screening for IGF1R haploinsufficiency. Further investigations are necessary to delineate how comparable IGF1R availability leads to the wide spectrum of clinical phenotypes and variable responsiveness to rhGH therapy.
BACKGROUND: The growth-promoting effects of IGF-I is mediated through the IGF-I receptor (IGF1R), a widely expressed cell-surface tyrosine kinase receptor. IGF1R copy number variants (CNV) can cause pre- and postnatal growth restriction or overgrowth. METHODS: Whole exome sequence (WES), chromosomal microarray, and targeted IGF1R gene analyses were performed on 3 unrelated children who share features of small for gestational age, short stature, and elevated serum IGF-I, but otherwise had clinical heterogeneity. Fluorescence-activated cell sorting (FACS) analysis of cell-surface IGF1R was performed on live primary cells derived from the patients. RESULTS: Two novel IGF1R CNV and a heterozygous IGF1R nonsense variant were identified in the 3 patients. One CNV (4.492 Mb) was successfully called from WES, utilizing eXome-Hidden Markov Model (XHMM) analysis. FACS analysis of cell-surface IGF1R on live primary cells derived from the patients demonstrated a ∼50% reduction in IGF1R availability associated with the haploinsufficiency state. CONCLUSION: In addition to conventional methods, IGF1R CNV can be identified from WES data. FACS analysis of live primary cells is a promising method for efficiently evaluating and screening for IGF1Rhaploinsufficiency. Further investigations are necessary to delineate how comparable IGF1R availability leads to the wide spectrum of clinical phenotypes and variable responsiveness to rhGH therapy.
Authors: Andrew Dauber; Yongguo Yu; Michael C Turchin; Charleston W Chiang; Yan A Meng; Ellen W Demerath; Sanjay R Patel; Stephen S Rich; Jerome I Rotter; Pamela J Schreiner; James G Wilson; Yiping Shen; Bai-Lin Wu; Joel N Hirschhorn Journal: Am J Hum Genet Date: 2011-11-23 Impact factor: 11.025
Authors: Menachem Fromer; Jennifer L Moran; Kimberly Chambert; Eric Banks; Sarah E Bergen; Douglas M Ruderfer; Robert E Handsaker; Steven A McCarroll; Michael C O'Donovan; Michael J Owen; George Kirov; Patrick F Sullivan; Christina M Hultman; Pamela Sklar; Shaun M Purcell Journal: Am J Hum Genet Date: 2012-10-05 Impact factor: 11.025
Authors: Peng Fang; Yoon Hi Cho; Michael A Derr; Ron G Rosenfeld; Vivian Hwa; Christopher T Cowell Journal: J Clin Endocrinol Metab Date: 2011-11-30 Impact factor: 5.958
Authors: D C M Veenma; H J Eussen; L C P Govaerts; S W K de Kort; R J Odink; C H Wouters; A C S Hokken-Koelega; A de Klein Journal: J Med Genet Date: 2009-12-02 Impact factor: 6.318
Authors: T Siebler; W Lopaczynski; C L Terry; S J Casella; P Munson; D D De Leon; L Phang; K J Blakemore; R C McEvoy; R I Kelley Journal: J Clin Endocrinol Metab Date: 1995-12 Impact factor: 5.958
Authors: Joseph T Glessner; Alexander G Bick; Kaoru Ito; Jason Homsy; Laura Rodriguez-Murillo; Menachem Fromer; Erica Mazaika; Badri Vardarajan; Michael Italia; Jeremy Leipzig; Steven R DePalma; Ryan Golhar; Stephan J Sanders; Boris Yamrom; Michael Ronemus; Ivan Iossifov; A Jeremy Willsey; Matthew W State; Jonathan R Kaltman; Peter S White; Yufeng Shen; Dorothy Warburton; Martina Brueckner; Christine Seidman; Elizabeth Goldmuntz; Bruce D Gelb; Richard Lifton; Jonathan Seidman; Hakon Hakonarson; Wendy K Chung Journal: Circ Res Date: 2014-09-09 Impact factor: 17.367
Authors: Melanie R Shapiro; Timothy P Foster; Daniel J Perry; Ron G Rosenfeld; Andrew Dauber; James A McNichols; Andrew Muir; Vivian Hwa; Todd M Brusko; Laura M Jacobsen Journal: Horm Res Paediatr Date: 2020-10-28 Impact factor: 2.852
Authors: Paula Ocaranza; Monique Losekoot; Marie J. E. Walenkamp; Christiaan De Bruin; Jan M. Wit; Veronica Mericq Journal: J Clin Res Pediatr Endocrinol Date: 2019-03-12